KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Net Cash Flow (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Net Cash Flow for 15 consecutive years, with -$22.9 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 160.87% to -$22.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $60.6 million through Dec 2025, up 1158.31% year-over-year, with the annual reading at $60.6 million for FY2025, 1158.31% up from the prior year.
  • Net Cash Flow for Q4 2025 was -$22.9 million at Supernus Pharmaceuticals, down from $8.1 million in the prior quarter.
  • The five-year high for Net Cash Flow was $369.1 million in Q1 2023, with the low at -$437.5 million in Q2 2023.
  • Average Net Cash Flow over 5 years is -$7.9 million, with a median of -$11.8 million recorded in 2021.
  • Peak annual rise in Net Cash Flow hit 520.75% in 2023, while the deepest fall reached 858.05% in 2023.
  • Over 5 years, Net Cash Flow stood at -$11.8 million in 2021, then tumbled by 55.08% to -$18.4 million in 2022, then fell by 8.49% to -$19.9 million in 2023, then skyrocketed by 288.94% to $37.7 million in 2024, then tumbled by 160.87% to -$22.9 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$22.9 million, $8.1 million, and $28.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.